DelistingJul 31, 2026, 04:14 PM
Context Therapeutics Receives Nasdaq Delisting Notice
AI Summary
Context Therapeutics Inc. received a written notice from Nasdaq on July 29, 2026, indicating non-compliance with the Minimum Bid Price Rule. The company's common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days. Context Therapeutics has an initial 180-calendar-day period, until January 25, 2027, to regain compliance. The company intends to monitor its stock price and evaluate options to resolve the deficiency, though there is no assurance of regaining compliance.
Key Highlights
- Received Nasdaq delisting notice on July 29, 2026, for non-compliance with Minimum Bid Price Rule.
- Common stock failed to maintain a minimum closing bid price of $1.00 per share for 30 consecutive business days.
- Initial compliance period is 180 calendar days, until January 25, 2027.
- To regain compliance, common stock must close at $1.00 or more for a minimum of 10 consecutive business days.
- May be eligible for an additional 180-day period if other listing standards are met and intent to cure is notified.
Price Impact
More from CNTX